Adding adjuvants to fluoropyrimidine-based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an option worthy of serious consideration

2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients.

Cite

CITATION STYLE

APA

Wu, F., Zhou, C., Wu, B., Zhang, X., Wang, K., Wang, J., … Wang, G. (2020). Adding adjuvants to fluoropyrimidine-based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an option worthy of serious consideration. Journal of Cancer. Ivyspring International Publisher. https://doi.org/10.7150/jca.48337

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free